



MEMORANDUM OF UNDERSTANDING

Between:

the Association Belge de Médecine Nucléaire (BELNUC) /
Belgische Vereniging voor Nucleaire Geneeskunde (BELNUC)

and

the Belgian Hospital Physicists Association (BHPA)

Between

Association Belge de Médecine Nucléaire (BELNUC) / Belgische Vereniging voor Nucleaire
Geneeskunde (BELNUC)

Hippokrateslaan 10, 1200 Sint-Lambrechts-Woluwe, Belgium

(hereinafter referred to as "BELNUC")

And

Belgian Hospital Physicists Association (BHPA)

Laarbeeklaan 103, 1090 Jette, Belgium

(hereinafter referred to as "BHPA")

This Memorandum of Understanding ("MoU") is effective as of **3 September 2026** by and
between the Associations as mentioned above. The parties hereby express their shared
intentions as follows:

Article 1: Scope

This MoU reflects the intentions of BELNUC and BHPA to identify and formalise their collaboration in specific areas of common interest. Recognising the increasing complexity and multidisciplinary nature of nuclear medicine, both organisations acknowledge the value of closer cooperation between the nuclear medicine and medical physics communities they represent.

The purpose of this MoU is to set forth a framework of collaboration for advancing the mutual objectives of BELNUC and BHPA as they relate to the topics set out in Article 4 of this MoU, with the aim of supporting high-quality, safe, and innovative patient care through the complementary expertise of both associations.

Article 2: BELNUC areas of responsibilities and activities

BELNUC is the national, multidisciplinary professional and scientific society dedicated to nuclear medicine in Belgium. Its object is to promote, in the broadest sense, the use of radio-isotopes in medicine across scientific research, education, and evidence-based, high-quality clinical applications, while safeguarding the multidisciplinary character of the discipline. Membership is open to all who are involved in the preparation and/or application of radio-isotopes in the medical field, including nuclear medicine physicians, radiopharmacists, medical physicists, and technologists. BELNUC pursues this object through activities such as, but not limited to:

- Organising scientific congresses, seminars, and continuing-education activities;
- Defining competence criteria and criteria for the administration of radio-isotopes to patients, together with standards for the protection of personnel, in consultation with the competent authorities for radiation protection and radiopharmaceuticals;
- Promoting collaboration with other organisations and public authorities, both national and international, in which BELNUC is involved as a stakeholder, and fostering the exchange of information among its members;
- Supporting working groups, research, and professional development within the field of nuclear medicine.

Article 3: BHPA areas of responsibilities and activities

The Belgian Hospital Physicists Association (BHPA) is the national association for hospital physicists in Belgium. Its purpose is to support the professional, scientific, and societal role of hospital physicists and to promote cooperation, knowledge sharing, and professional development in the fields where hospital physics is applied, including radiotherapy, medical

imaging, nuclear medicine, and related domains such as MRI. The BHPA represents its members and contributes to the quality, safety, and responsible use of medical technologies in healthcare.

The BHPA pursues this purpose through activities such as, but not limited to:

- Organising meetings, study days, congresses, workshops, and other scientific or professional events;
- Facilitating the exchange of information, experience, and good practice among members;
- Promoting education, training, and continuing professional development for hospital physicists and related professionals;
- Supporting the creation and dissemination of publications, legislation via technical reports, recommendations, and other informational material;
- Establishing and supporting working groups, committees, and other initiatives that contribute to the association's purpose;
- Representing the interests of hospital physicists before public authorities, healthcare institutions, professional bodies, and other relevant stakeholders;
- Encouraging cooperation with national and international organisations active in hospital physics, medical physics, and related disciplines;
- Undertaking any other activities that are directly or indirectly connected with the achievement of its purpose.

Article 4: Areas of Collaboration

BELNUC and BHPA agree to collaborate, where appropriate and within their respective capabilities, on activities such as, but not limited to:

1. Scientific and educational exchange

This may include inviting speakers from each organisation to participate in the other's annual congress, symposium, or training events; organising joint sessions at meetings on topics of common interest (e.g. dosimetry, theranostics, AI in nuclear medicine); and

promoting mutual participation in workshops, webinars, and continuing-education initiatives.

2. Joint working groups

Both organisations may explore the establishment of joint expert working groups, or facilitate cooperation between existing working groups, on topics such as:

- Implementation of new radionuclide therapies;
- Quality assurance guidelines;
- AI validation and clinical integration.

3. Policy and regulatory alignment

The parties may exchange information on national and European regulatory developments, coordinate input towards consultations where appropriate, and explore opportunities to issue joint statements on key topics. Any position issued jointly remains subject to prior board approval of both organisations in accordance with their respective internal procedures.

4. Communication and visibility

The parties may share relevant announcements, initiatives, and publications via their respective communication channels (website, newsletter, social media), as applicable, and identify opportunities for joint outreach towards stakeholders.

5. Research and innovation

The parties may facilitate networking between nuclear medicine physicians, radiopharmacists, technologists, and medical physics experts and support multidisciplinary projects, including those related to emerging technologies.

6. Regular exchange and update via the nominated liaison representatives (as described under Article 5 of this MoU).

If not differently agreed, each party shall cover the costs arising from its own delegation(s). Costs resulting from joint projects are subject to prior evaluation and agreement of all parties involved, according to their respective internal approval procedures.

Article 5: Liaison Representatives

Both BELNUC and BHPA will appoint a liaison representative to serve as the official contact and to coordinate the activities of each organisation in carrying out this MoU. BELNUC will be represented by one of its Board members. BHPA will be represented by one of its Board

members. Any changes in representation will be communicated to other party as soon as they are known. Official statements or additions to this MoU may only be issued by the Boards of BELNUC and BHPA.

The Liaison Representatives are responsible for:

- Ensuring a constant and transparent communication flow, both between the organisations and internally;
- Proactive follow-up on agreed action items;
- Safeguarding each organisation's internal processes and standards, including but not limited to reporting and approval procedures.

Any changes in the appointed representatives or their responsibilities will be communicated to the other party as soon as they are known.

Article 6: Meetings and communication

The BELNUC and BHPA liaison representatives will be in regular exchange, mainly by means of electronic communication tools (e-mails, web-conferences). A bilateral alignment meeting between board representatives will, in principle, be held on an annual basis.

Physical meetings may be held if deemed necessary; the coverage of any related expenses is subject to upfront agreement in accordance with Article 4 of this MoU.

Article 7: Confidentiality, Use of material, Data protection

Material jointly produced under the scope of this MoU may be used and disseminated by both parties among their respective stakeholders, subject to mutual agreement on jointly authored outputs and to the confidentiality and data-protection provisions below.

All non-public information and data that one party shares with the other shall be treated as confidential. The receiving party shall not use or disclose any such information for any purpose beyond the scope of this MoU without the prior written consent of the disclosing party. This obligation does not apply to information that is or becomes publicly available other than through a breach of this MoU, or that a party is required to disclose by law.

BELNUC and BHPA shall comply with applicable European and Belgian data protection laws, including the General Data Protection Regulation (GDPR). Neither party shall process personal data acquired individually or jointly under this MoU without a valid legal basis and the necessary consent, and not for any purpose beyond the scope of this MoU.

Article 8: Duration

This MoU shall become effective upon signature by the authorised officials of BELNUC and BHPA and will remain in effect for an initial term of 3 years. After 3 years, this MoU may be reviewed and revised by mutual agreement of the parties.

Article 9: Collaboration partners and non-binding nature

BELNUC acknowledges BHPA as a preferred, non-exclusive partner for the topics set out in Articles 4 and 5 of this MoU in matters relating to medical physics, and BHPA acknowledges BELNUC as a preferred, non-exclusive partner for the topics set out in Articles 4 and 5 of this MoU in matters relating to nuclear medicine. This mutual preference confers no exclusivity or priority right, and each organisation remains independent in its governance and decision-making and free to collaborate with any other party.

Both parties intend to conduct the activities outlined in this MoU with goodwill, dedication, and in accordance with their best efforts and capabilities.

Nothing in this MoU shall be construed as creating any partnership, joint venture, agency, or employment relationship between the parties, nor as conferring any right, privilege, claim, or entitlement on either party or on any third party. Neither party is authorised to represent, act on behalf of, or bind the other, nor to use the other's name or logo or imply its endorsement, without the prior written consent of that party's Board. No rights or obligations of any kind may be inferred or derived from this MoU.

The present MoU sets out the general conditions and arrangements for future cooperation between the parties. It reflects the intention of both parties to collaborate and is not legally binding on the parties.

Signatures

For the Association Belge de Médecine
Nucléaire (BELNUC) / Belgische
Vereniging voor Nucleaire Geneeskunde
(BELNUC)

Name: Tim Van den Wyngaert

Title: President

Date: 31/3/2026

Signature:



For the Belgian Hospital Physicists
Association (BHPA)

Name: Jan Vandecasteele

Title: President

Date:

31/3/2026

Signature:

